Yarger Wealth Strategies LLC Sells 1,746 Shares of Johnson & Johnson (NYSE:JNJ)

Yarger Wealth Strategies LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 54.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,469 shares of the company's stock after selling 1,746 shares during the quarter. Yarger Wealth Strategies LLC's holdings in Johnson & Johnson were worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pacer Advisors Inc. raised its stake in Johnson & Johnson by 15.3% during the 2nd quarter. Pacer Advisors Inc. now owns 240,605 shares of the company's stock worth $35,167,000 after buying an additional 31,908 shares during the period. Sei Investments Co. raised its position in shares of Johnson & Johnson by 10.7% during the second quarter. Sei Investments Co. now owns 1,126,658 shares of the company's stock worth $164,672,000 after purchasing an additional 109,205 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Johnson & Johnson by 31.8% during the 2nd quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company's stock valued at $238,951,000 after purchasing an additional 394,518 shares in the last quarter. Kiely Wealth Advisory Group Inc. increased its stake in Johnson & Johnson by 5.7% during the 2nd quarter. Kiely Wealth Advisory Group Inc. now owns 1,847 shares of the company's stock worth $296,000 after purchasing an additional 99 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its holdings in Johnson & Johnson by 30.7% during the 2nd quarter. Summit Trail Advisors LLC now owns 45,920 shares of the company's stock worth $6,712,000 after buying an additional 10,789 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.74 during trading on Friday, hitting $147.03. 10,678,393 shares of the stock were exchanged, compared to its average volume of 6,880,262. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a fifty day moving average price of $148.51 and a 200-day moving average price of $156.03. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is presently 71.78%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. StockNews.com lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday. Bank of America cut their price target on Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating on the stock in a report on Friday. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective for the company. Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Finally, Guggenheim lifted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $174.29.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.